Last $57.51 USD
Change Today +0.68 / 1.20%
Volume 7.7M
MYL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

1000 Mylan Boulevard

Canonsburg, PA 15317

United States

Phone: 724-514-1800

Fax:

oximately 340 dosage strengths. EMEA The company’s generic pharmaceutical sales in EMEA are generated primarily by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries. In addition to selling pharmaceuticals under their International Nonproprietary Name (INN) (active ingredient), in certain European countries, there is a market for both branded generic products and ‘company-branded’ generic products. France In France, the company markets a portfolio, including both oral solid and injectable dosage forms, of approximately 280 products in an aggregate of approximately 940 dosage strengths. Italy In Italy, the company markets a portfolio of approximately 180 products in an aggregate of approximately 350 dosage strengths. U.K. In the U.K., the company markets a portfolio of approximately 180 products in an aggregate of approximately 360 dosage strengths. Spain In Spain, the company markets a portfolio of approximately 130 products in an aggregate of approximately 250 dosage strengths. The Netherlands In the Netherlands, the company markets a portfolio of approximately 230 products in an aggregate of approximately 460 dosage strengths. Germany In Germany, the company markets a portfolio of approximately 160 products in an aggregate of approximately 350 dosage strengths. Poland As part of the acquisition of Agila, the company acquired an injectable manufacturing facility in Poland. The facility specializes in the production of injectable doses, including ampoules, liquid vials, and pre-filled syringes. The company manufactures approximately 20 products in an aggregate of approximately 50 dosage strengths, primarily for distribution within Europe. In addition, it operates a commercial business in Poland focused on the generic prescription market. Other EMEA Locations The company has a presence in other European company-branded generic prescription markets, including Portugal. The company also operates in various other European markets, including Ireland, the Nordic countries (principally Sweden and Finland), Belgium, the Czech Republic, and Hungary. Additionally, it has an export business, which is focused on Africa and the Middle East. Rest of World The company markets generic pharmaceuticals in the Rest of World through subsidiaries in India, Australia, Japan, New Zealand, Brazil, and Taiwan. It also participates in a collaboration with Pfizer Japan Inc. (Pfizer Japan) to develop, manufacture, distribute, and market generic drugs in Japan. Additionally, through Mylan India, the company markets API to third parties and also supplies other Mylan subsidiaries. India Mylan India manufactures and supplies API for the company’s own products and pipeline, as well as for various third parties. Mylan India also produces a line of finished dosage form (FDF) products for the ARV market, which are sold outside of India. Additionally, Mylan India manufactures non-ARV FDF products that are marketed and sold to third parties by other Mylan operations around the world. In addition to the sale of FDF products, the company has approximately 275 APIs in the market or under development and it focuses its marketing efforts on regulated markets, such as the U.S. and the European Union (the ‘EU’). The company produces API for use in the manufacture of its own pharmaceutical products, as well as for use by third parties, in a range of categories, including anti-bacterials, central nervous system agents, anti-histamine/anti-asthmatics, cardiovasculars, anti-virals, anti-diabetics, anti-fungals, proton pump inhibitors, and pain management drugs. Mylan India commenced commercial operations in India starting with the launch of a portfolio of FDF ARV products for the treatment of HIV/AIDS. In June 2013, Mylan India added a portfolio of women’s health care products focused on hormone and infertility treatments along with nutritional supplements. In October 2013, Mylan’s partner, Biocon Limited (Biocon), received approval for Trastuzumab from the Drug Controller General of India. Trastuzumab is a biosimilar product that the company is developing in pa

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:US $57.51 USD +0.68

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Omnicare Inc $73.59 USD +0.49
Perrigo Co PLC $168.14 USD +3.29
UCB SA €65.79 EUR +0.77
WW Grainger Inc $257.81 USD +5.58
WESCO International Inc $76.99 USD +0.62
View Industry Companies
 

Industry Analysis

MYL

Industry Average

Valuation MYL Industry Range
Price/Earnings 24.8x
Price/Sales 2.9x
Price/Book 6.4x
Price/Cash Flow 23.4x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN INC, please visit www.mylan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.